<DOC>
	<DOCNO>NCT00649922</DOCNO>
	<brief_summary>To evaluate immunogeneicity Influenza virus standard 23-valent pneumococcal virus subject RA receiving adalimumab placebo</brief_summary>
	<brief_title>Assessment Effect Adalimumab Response Influenza Virus Pneumococcal Vaccines Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male/Females least 20 year age . Females postmenopausal least 1 year , surgically sterile , practice acceptable method birth control . Females negative pregnancy test screening . Diagnosis RA meet ACR criterion . Must discontinue TNF least 2 month prior baseline . In condition general good health . History significant sensitivity drug ; clinically significant drug alcohol abuse within past year ; active infection Listeria TB ; lymphoma leukemia ; sicklecell disease , splenectomy , malignancy within 5 year exception successfully treat nonmetastatic basal cell squamous cell carcinoma skin localize carcinoma situ cervix . History current acute inflammatory joint disease . Use TAMIFLU Symmetrel within 3 month study drug administration . Recent ( 3 month ) history influenza pneumococcal bacterial infection . Known positive human immunodeficiency virus ( HIV ) status . Positive hepatitis B hepatitis C virus . Positive PPD &gt; 5 mm . Chest xray calcify granulomas and/or pleural scar significant abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Vaccines adalimumab dose</keyword>
</DOC>